Lixte Biotech Enters and Terminates Agreements
Ticker: LIXT · Form: 8-K · Filed: Dec 22, 2025 · CIK: 1335105
Sentiment: neutral
Topics: material-agreement, corporate-action
Related Tickers: LIXT
TL;DR
Lixte Biotech signed and then ditched some big deals on Dec 16, 2025.
AI Summary
Lixte Biotechnology Holdings, Inc. reported on December 16, 2025, the entry into and termination of material definitive agreements. The company, incorporated in Delaware, is involved in the pharmaceutical preparations industry.
Why It Matters
This filing indicates significant corporate actions, including the initiation and subsequent cancellation of material agreements, which could impact the company's strategic direction and financial commitments.
Risk Assessment
Risk Level: medium — The simultaneous entry and termination of material definitive agreements suggest potential volatility or uncertainty in the company's business dealings.
Key Players & Entities
- LIXTE BIOTECHNOLOGY HOLDINGS, INC. (company) — Registrant
- December 16, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 202903526 (identifier) — IRS Employer ID
FAQ
What were the material definitive agreements entered into and subsequently terminated by Lixte Biotechnology Holdings, Inc. on December 16, 2025?
The filing states that Lixte Biotechnology Holdings, Inc. entered into and terminated material definitive agreements on December 16, 2025, but does not specify the nature or details of these agreements.
What is the primary business of Lixte Biotechnology Holdings, Inc. according to the filing?
Lixte Biotechnology Holdings, Inc. is classified under Standard Industrial Classification code 2834, which pertains to Pharmaceutical Preparations.
In which state is Lixte Biotechnology Holdings, Inc. incorporated?
Lixte Biotechnology Holdings, Inc. is incorporated in Delaware.
What is the SEC file number for Lixte Biotechnology Holdings, Inc.?
The SEC file number for Lixte Biotechnology Holdings, Inc. is 001-39717.
What is the fiscal year end for Lixte Biotechnology Holdings, Inc.?
The fiscal year end for Lixte Biotechnology Holdings, Inc. is December 31.
Filing Stats: 1,198 words · 5 min read · ~4 pages · Grade level 10.9 · Accepted 2025-12-22 17:29:32
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share LIXT The NASDAQ Stock Mar
- $4.09 — of Common Stock at an offering price of $4.09 per share (or $4.08999 per Pre-Funded W
- $4.08999 — n offering price of $4.09 per share (or $4.08999 per Pre-Funded Warrant) and Common Warr
- $3.96 — of Common Stock at an offering price of $3.96 per share. The Offering is expected t
- $4.3 million — sult in gross proceeds of approximately $4.3 million before deducting placement agent's fees
- $85,000 — agreed to reimburse the Placement Agent $85,000 for its legal fees. The foregoing sum
Filing Documents
- form8-k.htm (8-K) — 56KB
- ex4-1.htm (EX-4.1) — 132KB
- ex4-2.htm (EX-4.2) — 134KB
- ex5-1.htm (EX-5.1) — 21KB
- ex10-1.htm (EX-10.1) — 268KB
- ex10-2.htm (EX-10.2) — 88KB
- ex10-3.htm (EX-10.3) — 8KB
- ex99-1.htm (EX-99.1) — 17KB
- ex5-1_001.jpg (GRAPHIC) — 6KB
- ex10-2_001.jpg (GRAPHIC) — 27KB
- ex99-1_001.jpg (GRAPHIC) — 9KB
- ex99-1_002.jpg (GRAPHIC) — 5KB
- 0001493152-25-028850.txt ( ) — 1134KB
- lixt-20251216.xsd (EX-101.SCH) — 4KB
- lixt-20251216_def.xml (EX-101.DEF) — 26KB
- lixt-20251216_lab.xml (EX-101.LAB) — 36KB
- lixt-20251216_pre.xml (EX-101.PRE) — 25KB
- form8-k_htm.xml (XML) — 5KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: December 22, 2025 LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Registrant) By: /s/ Geordan Pursglove Geordan Pursglove Chairman of the Board and Chief Executive Officer